Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Lacripep

Phase 2

TTearSolutions, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Neurotrophic KeratitisRecruiting

Neurotrophic KeratitisPhase 2

Recruiting

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Neurotrophic Keratitis

NCT07568730

Clinical

Trials by Indication[1]

Neurotrophic Keratitis1 trial

A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep 4 μM Ophthalmic Solution in Subjects With Neurotrophic Keratitis

Recruiting·TTearSolutions, Inc.·Phase 2·NCT07568730·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lacripep. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lacripep. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — TearSolutions, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTearSolutions, Inc.

Related News